Cilengitide trifluoroacetate

Catalog No.S7077 Synonyms: EMD 121974, NSC 707544

For research use only.

Cilengitide (EMD 121974, NSC 707544) is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.

Cilengitide trifluoroacetate Chemical Structure

CAS No. 199807-35-7

Selleck's Cilengitide trifluoroacetate has been cited by 58 publications

Purity & Quality Control

Choose Selective Integrin Inhibitors

Biological Activity

Description Cilengitide (EMD 121974, NSC 707544) is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.
Targets
αvβ3 receptor [1]
(Cell-free assay)
αvβ5 receptor [2]
(Cell-free assay)
4.1 nM 79 nM
In vitro

Cilengitide is a cyclized pentapeptide peptidomimetic designed to compete for the arginine-glycine-aspartic acid (RGD) peptide sequence that regulates integrin-ligand binding. Cilengitide selectively and potently blocks the ligation of theαvβ3 andαvβ5 integrins to provisional matrix proteins such as vitronectin, fibronectin, fibrinogen, von Willebrand factor, osteopontin, and others. [1] Cilegitide inhibits angiogenesis in vitro. 10 μM Cilengitide completely inhibits attachment of BAE, BME and HUVE cells on vitronectin and fibronectin. Cilengitide inhibits in vitro angiogenesis of BAE cells on three-dimensional collagen and fibrin gels pretreated with FGF-2(or VEGF-A) with IC50 of 15 μM and 8 μM, 4 μM and 3 μM, respectively. [2] Cilengitide blocks proliferation and induces apoptosis of endothelial cells as well as differentiation of human endothelial precursor cells (EPCs). 50 μg/mL Cilengitide completely inhibits the proliferation of human microvascular endothelial cell line HMEC-1 and leads to apoptosis in ~30% cells. [3] 1.0 μM Cilengitide treating for 9 days inhibits the proliferation of EPCs by nearly 40%. 1 μM Cilengitide inhibits the differentiation of EPCs by more than 80% at 14 days. [4] Cilengitide inhibits adhesion and induces apoptosis of tumor cells. 25 μg/mL Cilengitide causes detachment of DAOY cells (medulloblastoma) and U87MG cells (glioblastoma) from vitronectin and tenascin by more than 60%. 25 μg/mL Cilengitide induces a nearly 50% apoptosis rate of these cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
G28 MlPuSpVv[3Srb36gRZN{[Xl? MojEOVAh|rypL33s MoDYN|AwPjBxMUKwJI1qdg>? MXPpcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gSmFMNCCVcnOgZY5lKEGtdB?= MlXRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMUSwNFUoRjF7MUG0NFA2RC:jPh?=
HMEC-1  M4H4eWZ2dmO2aX;uJGF{e2G7 M4LOdlIxNzRyL{[wJO69\y:vbB?= NWLTSopPcW6qaXLpeJMhTkGNIHHu[EBUemQEoB?= NVSzdmFPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNVQxODVpPkG5NVE1ODB3PD;hQi=>
G44 M1HlU2Fxd3C2b4Ppd{BCe3OjeR?= MXyxM|UwPTBizsznM41t MmnSNlQhcA>? M3;SZolv\HWlZYOgZZBweHSxc3nz M{\YfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUG0NFA2Lz5zOUGxOFAxPTxxYU6=
G28 M1;rZ2Fxd3C2b4Ppd{BCe3OjeR?= MkfTNU82NzVyIN88[{9udA>? MmjENlQhcA>? M2O5Volv\HWlZYOgZZBweHSxc3nz Mnz6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMUSwNFUoRjF7MUG0NFA2RC:jPh?=
G44 NU\iXHVWWHKxbHnm[ZJifGmxbjDBd5NigQ>? MnzUNU82NzVyIN88[{9udA>? NYj3fodOOjRxNEivO|IhcA>? MoHSbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NHfEWnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGxOFAxPSd-MUmxNVQxODV:L3G+
G28 MWXQdo9tcW[ncnH0bY9vKEG|c3H5 NG\0UmYyNzVxNUCg{txoN22u MlXONlQwPDhxN{KgbC=> NHe4cmFqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M1ji[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUG0NFA2Lz5zOUGxOFAxPTxxYU6=
HMEC-1  MWfBdI9xfG:|aYOgRZN{[Xl? MYKxM|UwPTBizsznM41t MXiyOEBp M1\aTolv\HWlZYOgZZBweHSxc3nz MlzXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMUSwNFUoRjF7MUG0NFA2RC:jPh?=
HMEC-1  MojjVJJwdGmoZYLheIlwdiCDc4PhfS=> NUfvdJh1OS93L{WwJO69\y:vbB?= MkPJNlQwPDhxN{KgbC=> MUTpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MmK5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMUSwNFUoRjF7MUG0NFA2RC:jPh?=
HMEC-1  M2fUfmZ2dmO2aX;uJGF{e2G7 NFLWdW4yNzVxNUCg{txoN22u NH[ybGkzPCCq NWrIOW91cW6mdXPld{BiKGSxc3Wg[IVx\W6mZX70JIRmfGGlaH3lcpTDqA>? NX\rOYIzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNVQxODVpPkG5NVE1ODB3PD;hQi=>
LNT-229  MlnzSpVv[3Srb36gRZN{[Xl? MWCwMlEwOS9zMDFOwG0> M1frTlI1KGh? NGjteWxqdXCjaYLzJJRp\SCjZHjld4lwdiCxZjDj[YxteyC2bzD2bZRzd26nY4TpckBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ{MUG3NUc,OTl{MkGxO|E9N2F-
T98G Mn3USpVv[3Srb36gRZN{[Xl? NFLIcGcxNjFxMT:xNEDPxE1? MWWyOEBp MUXpcZBicXK|IITo[UBi\Ginc3nvckBw\iClZXzsd{B1dyC4aYTyc45m[3SrbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ{MUG3NUc,OTl{MkGxO|E9N2F-
LN-18 M1jDfmZ2dmO2aX;uJGF{e2G7 NHy5UnYxNjFxMT:xNEDPxE1? MormNlQhcA>? MnzXbY1x[Wm{czD0bIUh[WSqZYPpc44hd2ZiY3XscJMhfG9idnn0do9v\WO2aX6gbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NHjrdHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUKyNVE4OSd-MUmyNlEyPzF:L3G+
LN-308 MlfqSpVv[3Srb36gRZN{[Xl? MYGwMlEwOS9zMDFOwG0> Mn;UNlQhcA>? MUHpcZBicXK|IITo[UBi\Ginc3nvckBw\iClZXzsd{B1dyC4aYTyc45m[3SrbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M3jGc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkKxNVcyLz5zOUKyNVE4OTxxYU6=
U87MG MlzvSpVv[3Srb36gRZN{[Xl? NWHJPZVPOC5zL{GvNVAh|ryP MW[yOEBp NX7PeopQcW2yYXnyd{B1cGViYXTo[ZNqd25ib3[gZ4VtdHNidH:geol1em:wZXP0bY4hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> Mon6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{MkGxO|EoRjF7MkKxNVcyRC:jPh?=
U87  MXnGeY5kfGmxbjDBd5NigQ>? MYCwMVI2KM7:Zz;tUC=> M1PRRlEzKGkEoB?= NH7reVJqdmS3Y3XzJIF2fG:yaHHnfUBld3OnIHTldIVv\GWwdHz5 M4nUWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{i4N|Q{Lz5{MUe4PFM1OzxxYU6=
U251 NWSzSWFtTnWwY4Tpc44hSXO|YYm= NUD4fpM5OC1{NTFOwIcwdUx? NWThOYZbOTJiaNMg NX\2RVd3cW6mdXPld{BifXSxcHjh[5kh\G:|ZTDk[ZBmdmSnboTsfS=> NUf6d4xVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3PFg{PDNpPkKxO|g5OzR|PD;hQi=>
U87  M1vxVWFxd3C2b4Ppd{BCe3OjeR?= M{HGSVI2KM7:Zz;tUC=> NV21OlJjOjRxNEigbC=> NVLuc3VpcW6mdXPld{BieG:ydH;zbZMh[XRiNEigbEB{cWewaX\pZ4FvfGy7 NWDxdnliRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3PFg{PDNpPkKxO|g5OzR|PD;hQi=>
U251 MlTWRZBweHSxc3nzJGF{e2G7 MnnGNlUh|rypL33M NYKwfWVHOjRxNEigbC=> MXHpcoR2[2W|IHHwc5B1d3OrczDheEA1QCCqIIPp[45q\mmlYX70cJk> Mm[xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5OEizOFMoRjJzN{i4N|Q{RC:jPh?=
U87  NX3MSno4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHT2Z24xNTJ3IN88[{9uVA>? MnfnNE01QCCq M3ThU4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> NFTPfmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe4PFM1Oyd-MkG3PFg{PDN:L3G+
U251 NILNbW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{P6WVAuOjVizsznM41N M{\pUlAuPDhiaB?= M2nOUYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd6OEO0N{c,OjF5OEizOFM9N2F-
U251MG M3;2ZWFxd3C2b4Ppd{BCe3OjeR?= M2LtXlEhyrWP NYX1ZoxFPDhiaB?= MmS4bY5lfWOnczDhdI9xfG:|aYO= NEDTNmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O1OFgxPyd-MkOzOVQ5ODd:L3G+
U87MG NHXsUmRCeG:ydH;zbZMhSXO|YYm= M1TN[|EhyrWP M3PhU|Q5KGh? NXTsV2FQcW6mdXPld{BieG:ydH;zbZM> MmjXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|NUS4NFcoRjJ|M{W0PFA4RC:jPh?=
U251MG NYiwdGhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfpPIhLOC1{NTFOwG0> NVTOU21OOjRxNEigbC=> MljEbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy MkD6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|NUS4NFcoRjJ|M{W0PFA4RC:jPh?=
U87MG NVHoPXA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUiwMVI2KM7:TR?= NEH4SZkzPC92ODDo MVPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= MlqwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|NUS4NFcoRjJ|M{W0PFA4RC:jPh?=
MCF-7  NYfwb|kxSXCxcITvd4l{KEG|c3H5 NVPHV2dpOC1{MDFOwG0> M2fNTVQ5KGh? MX7pcoR2[2W|IHHwc5B1d3Orcx?= MmLUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNUOxNFIoRjJ2MUWzNVAzRC:jPh?=
T-47D MnjzRZBweHSxc3nzJGF{e2G7 MmLzNE0zOCEQvF2= MXG0PEBp MmrObY5lfWOnczDhdI9xfG:|aYO= NVPBZ4VJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOVMyODJpPkK0NVU{OTB{PD;hQi=>
MCF-7  NWLqW5ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37jfFAuOjBizszN M2TIOVk3KGh? MWHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NGP1ZXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG1N|ExOid-MkSxOVMyODJ:L3G+
T-47D MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYqwMVIxKM7:TR?= NUTabFRMQTZiaB?= M4\YWolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MlnZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNUOxNFIoRjJ2MUWzNVAzRC:jPh?=
FaDu  MVHBdI9xfG:|aYOgRZN{[Xl? NH3XbWgzPcLiwsXNxsA> MX60POKhcMLi NETtcZFqdmS3Y3XzJIFxd3C2b4Ppdy=> MkjaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3NUewOVYoRjJ2NUW3NFU3RC:jPh?=
CAL27 Ml\pRZBweHSxc3nzJGF{e2G7 M2Wz[VI2yqEEtV5CpC=> NX23T4hKPDkEoHlCpC=> MUDpcoR2[2W|IHHwc5B1d3Orcx?= MmTaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3NUewOVYoRjJ2NUW3NFU3RC:jPh?=
SCC25 MXLBdI9xfG:|aYOgRZN{[Xl? MlLBNlXDqML3TdMg M{TVblQ5yqCqwrC= MVzpcoR2[2W|IHHwc5B1d3Orcx?= MlfyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3NUewOVYoRjJ2NUW3NFU3RC:jPh?=
FaDu  M4POemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\2elYvOjYkgKOyNFDDqML3TR?= MmLlO|IhcA>? MmnndoV{fWy2czDtc4RmemG2ZTyg[I9{\S2mZYDlcoRmdnRiZ4Lve5RpKGmwaHnibZRqd25? NHXHXYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW1O|A2Pid-MkS1OVcxPTZ:L3G+
CAL27 MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LPNVYvOjYkgKOyNFDDqML3TR?= MkiwO|IhcA>? NEPRdXNz\XO3bITzJI1w\GW{YYTlMEBld3OnLXTldIVv\GWwdDDndo94fGhiaX7obYJqfGmxbh?= NFP3NYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW1O|A2Pid-MkS1OVcxPTZ:L3G+
SCC25 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVW2MlI26oDVMkCwxsDDvU1? M3PjR|czKGh? NF;m[4Rz\XO3bITzJI1w\GW{YYTlMEBld3OnLXTldIVv\GWwdDDndo94fGhiaX7obYJqfGmxbh?= NEL5NlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW1O|A2Pid-MkS1OVcxPTZ:L3G+
H28 MnzoR4VtdCCYaXHibYxqfHliQYPzZZk> NG[zVlQyKG6PLUKwNEDPxE1? NHXFfGI4OiCq NHXZNpNl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NEDSO4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW5OVI4PCd-MkS1PVUzPzR:L3G+
MM05 NF;xToRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHm0Z2QyKG6PLUKwNEDPxE1? Mo[3O|IhcA>? M4jmc4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NUXTe4hpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1PVUzPzRpPkK0OVk2Ojd2PD;hQi=>
MSTO-211H NGrHdIxE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MX2xJI5ONTJyMDFOwG0> NESze3o4OiCq MlTs[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV7NUK3OEc,OjR3OUWyO|Q9N2F-
REN NX\2NlFYS2WubDDWbYFjcWyrdImgRZN{[Xl? NFvVbVEyKG6PLUKwNEDPxE1? NHjhZmQ4OiCq NF:wZXJl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= M1TUbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUm1Nlc1Lz5{NEW5OVI4PDxxYU6=
LN-308  M1W0dGZ2dmO2aX;uJGF{e2G7 NUDqNnRKOTEkgJpOwI0> M2jqTFI1KGh? MXHEUXNQyqB? NHTldWNz\WS3Y3XzJGFpWiCycn;0[YlvKGyndnXsd{BidmRiRGLFJJJmeG:{dHXyJIFkfGm4aYT5 NUHYOpJDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1NFAxPTZpPkK2OVAxODV4PD;hQi=>
HaCaT  MVjGeY5kfGmxbjDBd5NigQ>? NEjDfFcyOOLCid88cS=> MnHWOFghcA>? MVzEUXNQyqB? MYXy[YR2[2W|IGTHSk3PujMEoH3SUmEh\XiycnXzd4lwdg>? Mlf1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3MECwOVYoRjJ4NUCwNFU3RC:jPh?=
S-24 MnrZSpVv[3Srb36gRZN{[Xl? M4rjXFEwOTEkgJpOwI0> NWPXNIc4OjRiaB?= Mn\VSG1UV8Li M3PWRZJm\HWlZYOgSHJGKHKncH;yeIVzKGGldHn2bZR6 NXHUPZgzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1NFAxPTZpPkK2OVAxODV4PD;hQi=>
ZH-161 NH\hXGZHfW6ldHnvckBCe3OjeR?= Mnz6NU8yOOLCid88cS=> MnftNlQhcA>? NUHSSXJNTE2VT9Mg NGHySFBz\WS3Y3XzJGRTTSC{ZYDvdpRmeiCjY4Tpeol1gQ>? NHTt[VY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkWwNFA2Pid-Mk[1NFAxPTZ:L3G+
LN-308  Mly2SpVv[3Srb36gRZN{[Xl? NHjPeHEyNzFyL{GwNQKBkc7:bR?= MVWyOEBp MXXEUXNQyqB? MmjTdoVlfWOnczDEVmUhemWyb4L0[ZIh[WO2aY\peJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjVyMEC1Okc,OjZ3MECwOVY9N2F-
M21 MoTkSpVv[3Srb36gZZN{[Xl? MYCxJIhz NH7PTGNDcW6maX7nJIFn\mmwaYT5JJRwKGmwdHXndolvKGGucHjhek9j\XSjMzDo[ZRmem:maX3ldkBqdiCqdX3hckBOOjFiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBqdnSnZ4Lpck1u\WSrYYTl[EBpfW2jbjDNNlEh[2WubDDh[Ihme2mxbjD0c{B3cXS{b37lZ5RqdiCjZoTldkAyKGi{IHnuJJBz\XOnbnPlJI9nKE2wQ3yyMEBKSzVyIE2gNE4xODB2IN88UU4> NED4NGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1N|gyPCd-Mk[3OVM5OTR:L3G+
HEK293T NYrtN2lzTnWwY4Tpc44h[XO|YYm= M{OwN|IhcHK| MnjxRolv\GmwZzDh[oZqdmm2eTD0c{B{d2y3YnzlJJRzfW6lYYTl[EBpfW2jbjDy[YNwdWKrbnHueEBH[y22YXfn[YQh[WyyaHHWZoV1[TNiYX7kJIlvfGWpcnnud{B4\XKnIHX4dJJme3OnZDDpckBJTUt{OUPUJINmdGy|IHHmeIVzKDJiaILzJIJ6KGOxbYDleIl1cW:wIFXMTXNCNWyra3WgZZN{[XluIFnDOVAhRSByLkCwNFUyKM7:TT6= NUDTTlIzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVUxQTZpPkK0NFk2ODl4PD;hQi=>
HT-29 M1jHW2Z2dmO2aX;uJIF{e2G7 NEXxfIkzKGi{cx?= MWHBcpRi\2:waYP0JIFkfGm4aYT5JIF1KGmwdHXndolvKGGucHjhWoJmfGF3IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJGhVNTJ7IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBk\WyuIHHkbIV{cW:wIITvJJZqfHKxbnXjeIlvKGGodHXyJFIhcHK|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvOTJizszNMi=> MljYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|NUG1PVQoRjJ6M{WxOVk1RC:jPh?=
HEK293 NVX3PY1ETnWwY4Tpc44h[XO|YYm= MUCyJIhzew>? M1OyU2FvfGGpb37pd5Qh[WO2aY\peJkh[XRiaX70[YdzcW5iYXzwbIFX[mW2YUOgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJIFlcGW|aX;uJJRwKG[rYoLpco9o\W5iYX\0[ZIhOiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5{MjFOwG0v MkLiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|NUG1PVQoRjJ6M{WxOVk1RC:jPh?=
SKOV3 M{W2UWZ2dmO2aX;uJIF{e2G7 NFTWV5IzKGi{cx?= NXz1bWw6SW62YXfvcol{fCCjY4Tpeol1gSCjdDDpcpRm\3KrbjDhcJBp[V[kZYThN4FteGijVnLleIE2KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIGPLU3Y{KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKGGmaHXzbY9vKHSxIH\pZpJqdm:pZX6gZYZ1\XJiMjDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iMD6zO{DPxE1w M{nXUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{WxOVk1Lz5{OEO1NVU6PDxxYU6=
U87MG NWXZe4FqTnWwY4Tpc44h[XO|YYm= MYKxNFAhdk1? NYf5dYV3OjRiaILz M1\E[mlvcGmkaYTpc44hd2ZiYXzwbIFX[mW2YUOgbY51\We{aX6gbY4hcHWvYX6gWVg4VUdiY3XscJMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gdFU{KGGlY4XteYxifGmxbjDheEAyODBibl2gZYZ1\XJiMkSgbJJ{KGK7IGfld5Rmem5iYnzveEBu\XSqb3S= NV7tWZZPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O|U{ODNpPkK5O|c2OzB|PD;hQi=>
U87MG M{jJV2Z2dmO2aX;uJIF{e2G7 M33OUFExOCCwTR?= NEH0Z|EzPCCqcoO= Mnn2TY5pcWKrdHnvckBw\iCjbIDoZXZj\XSjMzDpcpRm\3KrbjDpckBpfW2jbjDVPFdOTyClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDwOVMh[WOldX31cIF1cW:wIHH0JFExOCCwTTDh[pRmeiB{NDDodpMhcW5icILld4Vv[2Vib3[gUWROOiCrbnjpZol1d3JiboX0cIlvNTNiYomgW4V{fGW{bjDicI91KG2ndHjv[C=> MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd5NUOwN{c,Ojl5N{WzNFM9N2F-
U87MG NIrRVFRHfW6ldHnvckBie3OjeR?= M3Xwd|ExOCCwTR?= NHHQTmMzPCCqcoO= M4L1TmlvcGmkaYTpc44hd2ZiYXzwbIFX[mW2YUOgbY51\We{aX6gbY4hcHWvYX6gWVg4VUdiY3XscJMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gdFU{KGGlY4XteYxifGmxbjDheEAyODBibl2gZYZ1\XJiMkSgbJJ{KGmwIIDy[ZNmdmOnIH;mJG1FVTJiaX7obYJqfG:{IH71eIxqdi1|IHHu[EBOTE12IHnubIljcXSxcjDTTk0yPzJ{NUWwJIJ6KFenc4Tldo4h[myxdDDt[ZRpd2R? M33Yc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{e1N|A{Lz5{OUe3OVMxOzxxYU6=
U87MG M1nmZ2Z2dmO2aX;uJIF{e2G7 MWexNFAhdk1? NWfwfmVoQCCqcoO= MnywTY5pcWKrdHnvckBw\iCjbIDoZXZj\XSjMzDpcpRm\3KrbjDpckBpfW2jbjDVPFdOTyClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDNSG0zKG2UTlGg[ZhxemW|c3nvckBifCBzMECgcm0h[W[2ZYKgPEBpenNiaX6gdJJme2WwY3Wgc4YhVUSPMjDpcohq[mm2b4KgcpV1dGmwLUOgZY5lKE2GTUSgbY5pcWKrdH;yJHNLNTF5MkK1OVAh[nliUmStVGNTKG2ndHjv[C=> M3rMTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{e1N|A{Lz5{OUe3OVMxOzxxYU6=
U87MG MlzCSpVv[3Srb36gZZN{[Xl? M2DVN|ExOCCwTR?= MnvKNlQhcHK| NHLEZmZKdmirYnn0bY9vKG:oIHHsdIhiXmKndHGzJIlvfGWpcnnuJIlvKGi3bXHuJHU5P02JIHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJHBWVUFibWLORUBmgHC{ZYPzbY9vKGG2IEGwNEBvVSCjZoTldkAzPCCqcoOgZpkhWlRvUFPSJI1mfGixZB?= NF[5U|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe3OVMxOyd-Mkm3O|U{ODN:L3G+
U87MG NX7RbJNvTnWwY4Tpc44h[XO|YYm= NYnRXXJFOTByIH7N M3XQd|I1KGi{cx?= NH\2PVlKdmirYnn0bY9vKG:oIHHsdIhiXmKndHGzJIlvfGWpcnnuJIlvKGi3bXHuJHU5P02JIHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJHBWVUFibWLORUBmgHC{ZYPzbY9vKGG2IEGwNEBvVSCjZoTldkAzPCCqcoOgbY4heHKnc3XuZ4Uhd2ZiTVTNNkBqdmirYnn0c5IhdnW2bHnuMVMh[nliUmStVGNTKG2ndHjv[C=> MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd5NUOwN{c,Ojl5N{WzNFM9N2F-
U87MG MkXJSpVv[3Srb36gZZN{[Xl? MorhNVAxKG6P MY[yOEBpenN? Mn25TY5pcWKrdHnvckBw\iCjbIDoZXZj\XSjMzDpcpRm\3KrbjDpckBpfW2jbjDVPFdOTyClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDQWW1CKG2UTlGg[ZhxemW|c3nvckBifCBzMECgcm0h[W[2ZYKgNlQhcHK|IHnuJJBz\XOnbnPlJI9nKE2GTUSgbY5pcWKrdH;yJHNLNTF5MkK1OVAh[nliUmStVGNTKG2ndHjv[C=> NHjxNmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe3OVMxOyd-Mkm3O|U{ODN:L3G+
U87MG M1vRcmZ2dmO2aX;uJIF{e2G7 Ml\FNVAxKG6P MX[yOEBpenN? Mkf5TY5pcWKrdHnvckBw\iCjbIDoZXZj\XSjMzDpcpRm\3KrbjDpckBpfW2jbjDVPFdOTyClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDQWW1CKG2UTlGg[ZhxemW|c3nvckBifCBzMECgcm0h[W[2ZYKgNlQhcHK|IHnuJJBz\XOnbnPlJI9nKE2GTUKgbY5pcWKrdH;yJI52fGyrbj2zJIFv\CCPRF20JIlvcGmkaYTvdkBUUi1zN{KyOVUxKGK7IGLUMXBEWiCvZYToc4Q> NEjK[HI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe3OVMxOyd-Mkm3O|U{ODN:L3G+
U87MG NXLtbphSTnWwY4Tpc44h[XO|YYm= Mn3hNVAxKG6P NV7jbYc6OjRiaILz NFLMb|VKdmirYnn0bY9vKG:oIHHsdIhiXmKndHGzJIlvfGWpcnnuJIlvKGi3bXHuJHU5P02JIHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJJAzOSCvUl7BJIV5eHKnc4Ppc44h[XRiMUCwJI5OKGGodHXyJFI1KGi{czDifUBTXC2SQ2KgcYV1cG:m NXn1Ro5lRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O|U{ODNpPkK5O|c2OzB|PD;hQi=>
U87MG NF7mfJdCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MVmxNFAhdk1? M{LieVczKGi{cx?= MmPIRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCXOEfNS{Bk\WyuczDheEAyODBibl2gZYZ1\XJiN{KgbJJ{KGmwIIDy[ZNmdmOnIH;mJG1FVTJiaX7obYJqfG:{IH71eIxqdi1|IHL5JG1VWyCjc4PhfS=> M2rsT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{e1N|A{Lz5{OUe3OVMxOzxxYU6=
U87MG M3H1dWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MUGxNFAhdk1? M3:3PVczKGi{cx?= NGrBbIFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGW4O21IKGOnbHzzJIF1KDFyMDDuUUBi\nSncjC3NkBpenNiaX6gdJJme2WwY3Wgc4YhVUSPMjDpcohq[mm2b4KgcpV1dGmwLUOgZY5lKE2GTUSgbY5pcWKrdH;yJHNLNTF5MkK1OVAh[nliTWTTJIF{e2G7 M4PSdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{e1N|A{Lz5{OUe3OVMxOzxxYU6=
U87MG NXLleZM2S2WubDDjfYNt\SCjc4PhfS=> MlHuNVAxKG6P MlLLNlQhcHK| Mmq1R4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gWVg4VUdiY3XscJMh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdyL1exJJBp[XOnIHH0JFExOCCwTTDh[pRmeiB{NDDodpM> M{HFRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{e1N|A{Lz5{OUe3OVMxOzxxYU6=
U87MG M2jVNWFvfGlvaX72ZZNqfmViYYPzZZk> M2PySlExKHWP NUPtW4U{OjRiaILz NVrweZp4SW62aT3pcpZie2m4ZTDhZ5Rqfmm2eTDpckBpfW2jbjDVPFdOTyClZXzsd{BifCBzMDD1UUBi\nSncjCyOEBpenNiYomgeJJidnO5ZXzsJIF{e2G7 NESzdZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe3OVMxOyd-Mkm3O|U{ODN:L3G+
U87MG MoXwRY51cS2rbo\hd4l3\SCjc4PhfS=> MmPiNVAhfU1? NXH4NpN7OjRiaILz NUS5XWx7SW62aT3pcpZie2m4ZTDhZ5Rqfmm2eTDpckBpfW2jbjDVPFdOTyClZXzsd{BifCBzMDD1UUBi\nSncjCyOEBpenNiaX6gdJJme2WwY3Wgc4YhVUSPMjDpcohq[mm2b4KgcpV1dGmwLUOgZY5lKE2GTUSgbY5pcWKrdH;yJHNLNTF5MkK1OVAh[nlidILhcpN4\WyuIHHzd4F6 MnS5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5N{WzNFMoRjJ7N{e1N|A{RC:jPh?=
Assay
Methods Test Index PMID
Western blot pFAK / p-AKT ; GLI1 19114005 31366904
Immunofluorescence VE-cadherin / β3 integrin 19212436
Growth inhibition assay Cell number 24153102
In vivo Cilengitide is activity against tumor growth and angiogenesis as single-agent. 100 μg Cilengitide induces a significant decrease in the number of CD 31+ vessels seen in tumors (2/high-power field) compared with control tumors (56/high-power field). 100 μg Cilengitide increases cellular apoptosis in the brain tumors of animals (2.2% apoptotic cells/high-power field) compared with those receiving the inactive peptide (1.7% cells/high-power field). Cilengitide treatment results in prolonged survival of the mice bearing melanoma xenografts M21 compared with control treatment group. (36.5 vs 17.3 days). [5] Cilengitide can augment the therapeutic benefit associated with cytotoxic agents including chemotherapy and radiation therapy in tumor models. Cilengitide (250 mg/dose) alone does not alter tumor growth of breast cancer xenografts when compared with untreated mice, but combined modality RIT (CMRIT) using RIT and six doses of Cilengitide (250 mg/dose) increases efficacy of treatment, with the cure rate for mice that receives only RIT increasing from 15 to 53%. CMRIT significantly increases apoptosis of tumor and endothelial cells 5 days, and decreases tumor proliferation. [6]

Protocol (from reference)

Kinase Assay:[2]
  • Integrin-binding competition assay:

    Recombinant soluble integrins are immobilized, and peptides, which are serially diluted in Tris-buffered saline (TBS++) (0.1% (w/v) BSA, 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2 10 μM MnCl2, 20 mM Tris-HCl; pH 7.4), are added in parallel with biotinylated vitronectin (to 1μg/mL). After a 3-h incubation at 37℃ and washing with Tris–buffered saline, bound ligand is detected by incubation with an antibiotin alkaline phosphatase-conjugated antibody (BioRad) followed by development with p-nitrophenyl phosphatase substrate. The reaction is stopped by the addition of NaOH and the color intensity read at 405 nm.

Cell Research:[3]
  • Cell lines: Human microvascular endothelial cell line HMEC-1
  • Concentrations: 1-50 μg/mL
  • Incubation Time: 3 days
  • Method: HMEC-1 (1×104 per well) are seeded on uncoated 48 well plates and incubated in medium containing 4% FCS with Cilengitide. After incubation for 72 hours at 37℃, cells are trypsinized and counted.
Animal Research:[5]
  • Animal Models: Human glioblastoma xenografts U87 MG
  • Dosages: 100μg
  • Administration: Daily i.p.

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 702.68
Formula

C29H41F3N8O9

CAS No. 199807-35-7
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(C)C1C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N1C)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N.C(=O)(C(F)(F)F)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01517776 Terminated Drug: Cilengitide|Drug: Temozolomide Gliomas Martin-Luther-Universität Halle-Wittenberg|Merck KGaA Darmstadt Germany January 2012 Phase 2
NCT01118676 Completed Drug: cilengitide radiochemotherapy Locally Advanced Non Small Cell Lung Cancer (NSCLC)* Institut Claudius Regaud|Merck KGaA Darmstadt Germany March 2010 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
The recommend vehicle is 30% propylene glycol, 5% Tween 80, 65% D5W at 30mg/ml, can you let me know if this is a suspension or clear solution?

Answer:
S7077 Cilengitide can be dissolved in 30% propylene glycol/5% Tween 80/65% D5W at 10 mg/ml as a clear solution.

Question 2:
Is Cilengitide a TFA salt?

Answer:
S7077 Cilengitide is actually a TFA salt, and the ratio between Cilengitide and TFA is 1:1.

Tags: buy Cilengitide trifluoroacetate | Cilengitide trifluoroacetate supplier | purchase Cilengitide trifluoroacetate | Cilengitide trifluoroacetate cost | Cilengitide trifluoroacetate manufacturer | order Cilengitide trifluoroacetate | Cilengitide trifluoroacetate distributor